On January 2, 2024 Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, reported the Investigational New Drug Application (IND) clearance to proceed by the U.S. Federal Drug Administration (FDA) to evaluate PAS-004, a macrocyclic MEK (1/2) inhibitor, in patients with MAPK pathway driven advanced solid tumors with a documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition (Press release, Pasithea Therapeutics, JAN 2, 2024, View Source [SID1234640979]). Pasithea expects to dose the first patient in the first quarter of 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The objectives of the dose escalation study are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics as well as anti-tumor responses of PAS-004 as monotherapy in up to 36 advanced cancer patients with preliminary early data expected as early as Q3 2024.

"Receiving a study may proceed notification from the US FDA is a significant milestone in Pasithea’s maturation into a clinical stage company developing PAS-004 as a potential best-in-class next generation MEK inhibitor and demonstrates our ability to execute on our objectives," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "We believe PAS-004 has the potential to improve clinical responses in cancer patients as a monotherapy as well as provide a more tolerable and better dosing profile. After we have established a preliminary recommended phase 2 dose, we will use this information to bridge to dosing for Neurofibromatosis type 1 patients. We look forward to working with our clinical partners to start this study in the United States and Eastern Europe shortly."

Administered orally, PAS-004 is expected to be an once day or less frequent dose which may provide better compliance rates as well as superior efficacy. PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials. Macrocycles exhibit unique drug-like profiles because of their cyclic structure, potentially improving bioavailability, binding affinity, and overall pharmacokinetics in comparison to acyclic counterparts.

About PAS-004

PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Blocking the phosphorylation of ERK can lead to cell death and inhibition of tumor growth. Existing FDA approved MEK inhibitors are marketed for a range of diseases, including certain cancers and neurofibromatosis type 1 (NF1). We believe these MEK inhibitors suffer from certain limitations, including known toxicities. Unlike current FDA approved MEK inhibitors, PAS-004 is macrocyclic, which we believe may lead to improved pharmacokinetic and safety (tolerability) profiles. Cyclization offers rigidity for stronger binding with drug target receptors. PAS-004 was designed to provide a longer half-life with what we believe is a better therapeutic window. Further, we believe the potency and safety profile that PAS-004 has demonstrated in preclinical studies may also lead to stronger and more durable response rates and efficacy, as well as better dosing schedules. PAS-004 has been tested in a range of mouse models of various diseases and has completed preclinical testing and animal toxicology studies. Additionally, PAS-004 has received orphan-drug designation from the FDA for the treatment of NF1.

On January 2, 2024 SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, reported that it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients (Press release, Mayo Clinic, JAN 2, 2024, View Source [SID1234638890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients, including individualized surgical planning, treatment, drug selection, and risk stratification. With the rapidly changing landscape in breast cancer, there is an urgent need to individualize care and identify opportunities where treatments, both surgical and medical, can be safely right sized to improve quality of life without compromising on outcomes.

Mayo Clinic physicians Judy C. Boughey, M.D., division chair of Breast and Melanoma Surgical Oncology and chair of the Mayo Clinic Comprehensive Cancer Center Breast Cancer Disease Group and Matthew Goetz, M.D., Enterprise Deputy Director of Translational Research and Director of Mayo Clinic Breast Cancer SPORE are part of the SimBioSys clinical advisory team to support the ongoing development and validation of these clinical software tools.

As part of the collaboration, SimBioSys has had access to and has been analyzing data from patients who participated in the Mayo Clinic-led BEAUTY clinical trial (NCT02022202). SimBioSys uses AI and data science to unlock spatial biophysical insights that will help clinicians better tailor treatment plans for each unique patient. SimBioSys will perform simulations using previously acquired data and, while validating the predictive accuracy of the platform, will also perform in-silico scenario analysis guided by the Mayo Clinic team.

SimBioSys has recruited a world-class team of scientists, computational biologists, data scientists, and software engineers that are developing software as a medical device cloud-based platform, TumorSightTM, to be used in the clinic during the treatment planning process. The company’s first product on the TumorSight platform, currently under FDA review, takes a patient’s standard of care DCE-MRI imaging to build a custom 3D digital model of their tumor. This innovative tool provides surgical oncologists with 3D spatial visualizations of breast cancer to support more effective surgical planning and patient consultations. Clear 3D "digital twin" renderings instantly display the tumor in the context of auto segmented anatomical structures (skin, vessels, chest, fat, gland and heart).

"In the crowded world of genomics, new approaches have many barriers to becoming a new standard of care," says Tushar Pandey, co-founder and CEO of SimBioSys. "SimBioSys complements current precision medicine techniques while only relying on readily available and previously acquired datasets such as imaging. We are delighted to collaborate with Mayo Clinic as we bring our innovative technology to patients."

Mayo Clinic has been designated a Comprehensive Cancer Center by the National Cancer Institute and is one of only 45 NCI-designated comprehensive centers in the United States. Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

On January 2, 2024 NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, reported the company will participate in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California (Press release, NeoGenomics Laboratories, JAN 2, 2024, View Source [SID1234638889]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of NeoGenomics’ management team will deliver a presentation followed by Q&A on Monday, January 8th at 5:15 p.m. PT/8:15 p.m. ET. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company’s website at ir.neogenomics.com.

On January 2, 2024 Diakonos Oncology Corporation ("Diakonos"), a clinical stage immuno-oncology company, reported that it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM). With the first patient enrolled in October 2021, DOC1021 has been administered to 16 patients across four dose levels (Press release, Diakonos Oncology, JAN 2, 2024, View Source [SID1234638888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, DOC1021 appears to be very safe and well tolerated as there have been no attributable serious adverse events observed from DOC1021. Additionally, 13 out of 16 patients remain alive today with the vast majority of patients still progression free.

"Completing the Phase 1 trial with both strong safety and efficacy signals was a critical step towards providing DOC1021 to all GBM patients," said Mike Wicks, Chief Executive Officer of Diakonos, "Our focus now shifts towards manufacturing optimization underway with Cellipont Bioservices and enrolling additional sites for the upcoming Phase 2 trial."

Additionally, DOC1021 also received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for malignant glioma, including treatment of newly diagnosed/refractory glioblastoma multiforme (GBM).

"Receiving the Orphan Drug Designation from the FDA is a valuable addition to our existing Fast Track Designation as it indicates that the cell therapy may be more broadly applicable to other oncological indications," said Ian Bellayr, PhD, Chief Regulatory Officer of Diakonos, "As we continue to accumulate more safety and efficacy data with time, Diakonos will continue to leverage other FDA programs to expedite development."

The FDA orphan drug designation provides seven years of marketing exclusivity along with other incentives such as tax credits, user fee waivers and federal grants to support clinical trials.

GBM is the most common and lethal malignant brain tumor with an annual incidence of 3.19 per 100,000 persons in the U.S. Despite aggressive management, median survival remains between 15 – 21 months with only 7% of patients surviving more than five years.

Diakonos’ dendritic cell vaccines are made with a patient’s dendritic cells and a sample of their tumor. This unique approach allows targeting of the complete cancer antigen profile without any genetic modification of the patient’s immune cells. Based on a discovery on how dendritic cells detect viral threats, the vaccines harness a natural immune response that targets and eliminates cancer cells as if they were virally infected.

Diakonos research indicates this approach generates a strong killer T cell response and stimulates immunological memory aimed at preventing the cancer’s recurrence. In addition to the Phase 1 trial of DOC1021 for GBM (NCT04552886), the company has two other vaccines in clinical development for pancreatic cancer (NCT04157127) and angiosarcoma (NCT05799612).

On January 2, 2024 Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, reported that Ken Drazan, MD, the company’s Chairman and Chief Executive Officer, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:30 a.m. PT (Press release, ArsenalBio, JAN 2, 2024, View Source [SID1234638887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!